Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,214,395
  • Shares Outstanding, K 67,579
  • Annual Sales, $ 250,730 K
  • Annual Income, $ -618,700 K
  • 60-Month Beta 1.61
  • Price/Sales 4.94
  • Price/Cash Flow N/A
  • Price/Book 1.23
Trade BLUE with:

Options Overview

Details
  • Implied Volatility 71.97%
  • Historical Volatility 34.53%
  • IV Percentile 72%
  • IV Rank 26.86%
  • IV High 124.24% on 03/26/21
  • IV Low 52.77% on 01/21/21
  • Put/Call Vol Ratio 0.31
  • Today's Volume 808
  • Volume Avg (30-Day) 364
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 6,411
  • Open Int (30-Day) 7,300

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -2.79
  • Number of Estimates 10
  • High Estimate -1.31
  • Low Estimate -3.62
  • Prior Year -2.94
  • Growth Rate Est. (year over year) +5.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.14 +4.84%
on 09/07/21
18.84 -4.62%
on 08/27/21
+0.38 (+2.16%)
since 08/20/21
3-Month
17.14 +4.84%
on 09/07/21
33.58 -46.49%
on 06/21/21
-15.18 (-45.79%)
since 06/18/21
52-Week
17.14 +4.84%
on 09/07/21
59.32 -69.71%
on 11/04/20
-38.69 (-68.28%)
since 09/18/20

Most Recent Stories

More News
Sickle Cell Disease Drugs Market: Industry Outlook, Classification, Demand, Regional Analysis and Forecast to 2030

Research Nester released a report titled which delivers a detailed overview of the global sickle cell disease drugs market in terms of market segmentation by treatment type, disease type, end-user, and...

EMMA : 1.7300 (unch)
GBT : 27.10 (-3.32%)
SIOX : 2.11 (-4.95%)
IMRA : 4.19 (-1.87%)
BLUE : 17.97 (-1.91%)
VRTX : 185.67 (-1.40%)
2seventy bio Announces Upcoming Investor Events

2seventy bio, the planned oncology spin-off of bluebird bio (NASDAQ: BLUE) announced today that it will host a series of investor events to share further detail on its research pipeline and strategy.

BLUE : 17.97 (-1.91%)
Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BLUE : 17.97 (-1.91%)
bluebird bio Secures $75 Million in Private Placement Equity Financing

--Business separation of bluebird and 2seventy expected to be completed in October 2021

BLUE : 17.97 (-1.91%)
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

--Marcela Maus named to bluebird bio board of directors

BLUE : 17.97 (-1.91%)
Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC

Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.

NVS : 82.80 (-0.81%)
BMY : 60.50 (-1.32%)
GILD : 70.96 (-0.91%)
BLUE : 17.97 (-1.91%)
BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc....

BLUE : 17.97 (-1.91%)
Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status

Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.

BMY : 60.50 (-1.32%)
GILD : 70.96 (-0.91%)
BLUE : 17.97 (-1.91%)
ALLO : 24.88 (-1.97%)
Biotech Stock Roundup: REGN Q2 Earnings Beat, BLUE, BYSI's Updates & More

The biotech sector was in focus last week on earnings results from Regeneron (REGN) and regulatory update from bluebird (BLUE) among others.

REGN : 640.89 (-1.69%)
SNY : 47.89 (-1.01%)
GILD : 70.96 (-0.91%)
SGEN : 159.06 (+1.82%)
BLUE : 17.97 (-1.91%)
BYSI : 15.36 (-32.96%)
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.

BMY : 60.50 (-1.32%)
RGEN : 306.05 (-0.28%)
BLUE : 17.97 (-1.91%)
SPRO : 19.00 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

3rd Resistance Point 18.95
2nd Resistance Point 18.66
1st Resistance Point 18.32
Last Price 17.97
1st Support Level 17.69
2nd Support Level 17.40
3rd Support Level 17.06

See More

52-Week High 59.32
Fibonacci 61.8% 43.21
Fibonacci 50% 38.23
Fibonacci 38.2% 33.25
Last Price 17.97
52-Week Low 17.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar